Ce protocole couvre la thrombocytémie essentielle dans la catégorie à risque intermédiaire : patients âgés de plus de 60 ans, JAK2 non muté, sans événement thrombotique antérieur et sans facteurs de risque cardiovasculaire.
L'objectif principal dans ce contexte est le soulagement des troubles vasomoteurs (microvasculaires) associés à la thrombocytémie essentielle.
DOI: 10.1002/ajh.27216
Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).
Twice-daily aspirin is also our current treatment choice for intermediate-risk disease, but combination of a cytoreductive drug with once-daily aspirin is a reasonable alternative in intermediate-risk patients with CV risk factors (Figure 5).
Low-dose aspirin therapy has also been shown to be effective in alleviating vasomotor (microvascular) disturbances associated with ET or PV.
View source ↗